Lucid Diagnostics (LUCD) announced its intention to offer shares of common stock through an underwritten public offering. Canaccord Genuity and BTIG are acting as joint bookrunners of the offering and Maxim Group is acting as co-manager of the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Positive Outlook for Lucid Diagnostics: Medicare Coverage and Clinical Support Boost EsoGuard’s Market Potential
- Lucid Diagnostics price target raised to $2.50 from $2 at BTIG
- Positive Outlook on Lucid Diagnostics’ EsoGuard Test Driven by Clinician Support and Potential Medicare Coverage
- Positive Outlook on Lucid Diagnostics Driven by EsoGuard’s Clinical Efficacy and Potential Medicare Coverage
- Lucid Diagnostics Earnings Call: Optimism Amid Challenges